Categories Health Care, U.S. Markets News

GSK teams up with Pfizer to announce major changes to business

GlaxoSmithKline plc (GSK) and Pfizer Inc. (PFE) have decided to combine their consumer health businesses in an all-equity transaction that is expected to close in the second half of 2019. GSK will own 68% of the joint venture, which the companies plan to spin off within three years of deal closure.

The combined annual sales from the consumer health units of both companies are estimated at over $12 billion, and the new JV is expected to have a market share that is significantly higher than its industry peers. It is estimated that the JV will provide annual cost savings of $632 million by 2022.

The deal with Pfizer is expected to benefit GSK’s adjusted EPS and free cash flow in the first year after completion. After completing the Pfizer deal, GSK plans to split its business into two units within three years.

One unit will focus on prescription medicines and vaccines while the other, formed by the spin-off of the consumer health business, will focus on over-the-counter (OTC) products. OTC products are said to be stable revenue sources while prescription medicines are likely to face volatility.

GSK reorganization gains steam with Tesaro buyout, sale of Asia unit

Although jobs are likely to be impacted by these changes, there are opportunities for cost savings across various parts of the business. This is a significant change for GSK under the leadership of CEO Emma Walmsley who took charge a year ago.

GSK has struck a number of deals this year, including an agreement to buy partner Novartis’ stake in their consumer healthcare JV for $13 billion. This month, GSK agreed to buy Massachusetts-based drug maker Tesaro for $5.1 billion. GSK also recently agreed to sell its nutrition business in India to Unilever for around $4 billion.

As of 1 pm ET, GSK’s stock was up 2.4% while Pfizer’s stock was up 0.73%.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips.

Most Popular

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Key metrics from Nike’s (NKE) Q2 2025 earnings results

NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net

FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips

Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top